Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides

Journal of Pharmaceutical Sciences

Volumn 103, Issue 5, 2014, Pages 1422-1432

  Forbes, Claire J ^a   McCoy, Clare F ^a   Murphy, Diarmaid J ^a   Woolfson, A David ^a   Moore, John P ^b   Evans, Abbey ^c   Shattock, Robin J ^c   Karl Malcolm, R ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

antiinfectives; drug delivery systems; formulation; gels; HIV AIDS; HIVmicrobicides; rheology; silicone elastomer; sustained release; viscosity

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BALANCE ACTIV; CYCLOMETHICONE; DIMETICONE; DYE; EMTRICITABINE; GYGEL; GYNOFIT; HYDROXYETHYLCELLULOSE; MARAVIROC; METRONIDAZOLE; MICROBICIDE; POLYCARBOPHIL; REPHRESH; SILANOL; SILASTIC; SILICONE GEL; UNCLASSIFIED DRUG; AGENTS USED INTRAVAGINALLY; ANTIRETROVIRUS AGENT; CELLULOSE; CYCLOHEXANE DERIVATIVE; DELAYED RELEASE FORMULATION; GEL; TOPICAL ANTIINFECTIVE AGENT; TRIAZOLE DERIVATIVE;

AQUEOUS SOLUTION; ARTICLE; CHEMICAL COMPOSITION; CHEMICAL MODEL; CHEMICAL MODIFICATION; CHEMICAL STRUCTURE; CONCENTRATION (PARAMETERS); CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG SOLUBILITY; HYDROPHILICITY; HYDROPHOBICITY; IN VITRO STUDY; MOLECULAR WEIGHT; PH; SIMULATION; STANDARD; SUSTAINED DRUG RELEASE; VAGINA DISCHARGE; VISCOSITY; ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; CHEMICAL PHENOMENA; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; FEMALE; GEL; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRAVAGINAL DRUG ADMINISTRATION; VAGINA;

ADMINISTRATION, INTRAVAGINAL; ANTI-INFECTIVE AGENTS, LOCAL; ANTI-RETROVIRAL AGENTS; CELLULOSE; CYCLOHEXANES; DELAYED-ACTION PREPARATIONS; FEMALE; GELS; HIV INFECTIONS; HIV-1; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; SILICONE ELASTOMERS; TRIAZOLES; VAGINA; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 84897970390     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23913     Document Type: Article

References (64)

1. Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L,. 2012. Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant Adenovirus HIV vaccine. J Infect Dis 206 (2): 258-266.
2. NIH news statement. NIH discontinues immunizations in HIV vaccine study. 2013. Accessed 21/02/2014, at: http://www.niaid.nih.gov/news/newsreleases/2013/ Pages/HVTN505April2013.aspx.
3. García-Lerma JG, Otten RA, Qari SH, Jackson E, Cong M, Masciotra S, Luo W, Kim C, Adams DR, Monsour M, Lipscomb J, Johnson JA, Delinsky D, Schinazi RF, Janssen R, Folks TM, Heneine W,. 2008. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 5 (2): e28.
4. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JH, Jaffe HS, Martinez AI, Burns DN, Glidden DV, iPrEx Study Team. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New Eng J Med 363: 2587-2599.
5. Food and Drug Administration Press Release. 2012. FDAHIV http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm311821.htm.
6. Cutler B, Justman J,. 2008. Vaginal microbicides and the prevention of HIV transmission. Lancet Infect Dis 8: 685-697.
7. Quifiones-Mateu ME, Vanham G,. 2012. HIV microbicides: Where are we now? Curr HIV Res 10: 1-2.
8. McGowan I,. 2010. Microbicides for HIV prevention: Reality or hope? Curr Opin Infect Dis 23: 26-31.
9. Morris GC, Lacey CJN,. 2010. Microbicides and HIV prevention: Lessons from the past, looking to the future. Curr Opin Infect Dis 23: 57-63.
10. Malcolm RK, Forbes CJ, Geer L, Veazey RS, Goldman L, Klasse PJ, Moore JP,. 2013. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J Antimicrob Chemother 68: 678-683.
11. Patton DL, Cosgrove Sweeney YT, Balkus JE, Rohan LC, Moncla BJ, Parniak MA, Hillier SL,. 2007. Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations. Antimicrob Agents Chemother 51: 1608-1615.
12. Karim SSA, Richardson BA, Ramjee G, Hoffman IF, Chirenje ZM, Taha T, Kapina M, Maslankowski L, Coletti A, Profy A, Moench TR, Piwowar-Manning E, Mâsse B, Hillier SL, Soto-Torres L,. 2011. On behalf of the HPTN 035 study team, safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 25: 957-966.
13. Nel AM, Coplan P, van der Wijgert JH, Kapiga SH, von Mollendorf C, Geubbels E, Vyankandondera J, Rees HV, Masenga G, Kiwelu I, Moyes J, Smythe SC,. 2009. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS 23: 1531-1538.
14. Nel AM, Coplan P, Smythe SC, McCord K, Mitchnick M, Kaptur PE, Romano J,. 2010. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses 26: 1181-1190.
15. Carballo-Diéguez A, Balan IC, Morrow K, Rosen R, Mantell JE, Gai F, Hoffman S, Maslankowski L, El-Sadr W, Mayer K,. 2007. Acceptability of tenofovir gel as a vaginal microbicides by US male participants in a Phase I clinical trial (HPTN 050), AIDS Care 19: 1026-1031.
16. HPTN 059 Press Statement. 2008. HPTN 059: A multi-center clinical trial evaluating the safety and acceptability of the candidate microbicide tenofovir topical gel. Accessed 21/02/2014, at: http://www.mtnstopshiv.org/news/studies/ hptn059/backgrounder.
17. Karim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany ABM, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, On behalf of the CAPRISA 004 trial group. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
18. MTN Press Statement. 2012. MTN statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women. Accessed 21/02/2014, at: http://www.mtnstopshiv.org/node/3909.
19. Gupta KM, Pearce SM, Poursaid AE, Aliyar HA, Tresco PA, Mitchnick MA, Kiser PF,. 2008. Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1. J Pharm Sci 97: 4228-4239.
20. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh SD,. 2005. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 56: 954-956.
21. Malcolm RK, Edwards KL, Kiser P, Romano J, Smith TJ,. 2010. Advances in microbicide vaginal rings. Antiviral Res 88S: S30-S39.
22. Nel A, Smythe S, Young K, Malcolm K, McCoy C, Rosenberg Z, Romano J,. 2009. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr 51: 416-423.
23. Woolfson AD, Malcolm RK, Morrow RJ, Toner CF, McCullagh SD,. 2006. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm 325: 82-89.
24. Fetherston SM, Geer L, Veazey RS, Goldman L, Murphy DJ, Ketas TJ, Klasse PJ, Blois S, La Colla P, Moore JP, Malcolm RK,. 2013. Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220. J Antimicrob Chemother 68: 394-403.
25. Singer R, Mawson P, Derby N, Rodriguez A, Kizima L, Menon R, Goldman D, Kenney J, Aravantinou M, Seidor S, Gettie A, Blanchard J, Piatak M, Lifson JD, Fernández-Romero JA, Robbiani M, Zydowsky TM,. 2012. An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci Trans Med 4: 150ra123
26. Moss JA, Malone AM, Smith TJ, Butkyavichene I, Cortez C, Gilman J, Kennedy S, Kopin E, Nguyen C, Sinha P, Hendry RM, Guenthner P, Holder A, Martin A, McNicholl J, Mitchell J, Pau CP, Srinivasan P, Smith JM, Baum MM,. 2012. Safety and pharmacokinetics of intravaginal rings delivering tenofovir in pig-tailed macaques. Antimicrob Agents Chemother 56: 5952-5960.
27. Malcolm K, Woolfson D, Russell J, Tallon P, McAuley L, Craig D,. 2003. Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. J Control Release 90: 217-225.
28. Veazey RS, Ketas TJ, Dufour J, Moroney-Rasmussen T, Green LC, Klasse PJ, Moore JP,. 2010. Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 202: 739-744.
29. Motakis D, Parniak MA,. 2002. A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46: 1851-1856.
30. D'Cruz OJ, Uckun FM,. 2006. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother 57: 411-423.
31. Andrews GP, Laverty TP, Jones DS,. 2009. Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm 71: 505-518.
32. Andrews GP, Donnelly L, Jones DS, Curran RM, Morrow RJ, Woolfson AD, Malcolm RK,. 2009. Characterization of the rheological, mucoadhesive, and drug release properties of highly structured gel platforms for intravaginal drug delivery. Biomacromolecules 10: 2427-2435.
33. Valenta C, Kast CE, Harich I, Bernkop-Schnürch A,. 2001. Development and in vitro evaluation of a mucoadhesive vaginal delivery system for progesterone. J Control Release 77: 323-332.
34. Valenta C., 2005. The use of mucoadhesive polymers in vaginal delivery. Adv Drug Deliv Rev 57: 1692-1712.
35. Vermani K, Garg S, Zaneveld LJD,. 2002. Assemblies for in vitro measurement of bioadhesive strength and retention characteristics in simulated vaginal environment. Drug Del Ind Pharm 28: 1133-1146.
36. Barnhart KT, Pretorius ES, Timbers K, Shera D, Shabbout M, Malamud D,. 2004. In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. Contraception 70: 498-505.
37. Brown J, Hooper G, Kenyon CJ, Haines S, Burt J, Humphries JM, Newman SP, Davis SS, Sparrow RA, Wilding IR,. 1997. Spreading and retention of vaginal formulations in post-menopausal women as assessed by gamma scintigraphy. Pharm Res 14: 1073-1078.
38. Chatterton BE, Penglis S, Kovacs JC, Presnell B, Hunt B,. 2004. Retention and distribution of two 99mTc-DTPA labelled vaginal dosage forms. Int J Pharm 271: 137-143.
39. Witter FR, Barditch-Crovo P, Rocco L, Trapnell CB,. 1999. Duration of vaginal retention and potential duration of antiviral activity for five nonoxynol-9 containing intravaginal contraceptives. Int J Gynecol Obstet 65: 165-170.
40. Forbes CJ, Lowry D, Greer L, Veazey RS, Shattock RJ, Klasse PJ, Mitchnick M, Goldman L, Doyle LA, Muldoon BCO, Woolfson AD, Moore JP, Malcolm RK,. 2011. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J Control Release 156: 161-169.
41. Dezzutti CS, Brown ER, Moncla B, Russo J, Cost M, Wang L, Uranker K, Kunjara RP, Na Ayudhya K, Pryke K, Pickett J, LeBlanc MA, Rohan RC,. 2012. Is wetter better? An evaluation of over-the-counter personal lubricants for safety and anti-HIV-1 activity. PLoS ONE 7 (11): e48328.
42. Wang l, Schnaare RL, Dezzutti C, Anton PA, Rohan LC,. 2011. Rectal microbicides:clinically relevant approach to the design of rectal specific placebo formulations. Aids Res Therapy 8: 12.
43. Mutu G, Sanders E, Mugo P, Anzala O, Haberer JE, Bangsberg D, Barin B, Rooney JF, Mark D, Chetty P, Fast P, Priddy FH,. 2012. Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers. PloS ONE 7: e33103.
44. TM 10 hydroalcoholic gels. Eur J Pharm Biopharm 54: 329-335.
45. Owen DH, Katz, DF,. 1999. A vaginal fluid simulant. Contraception 59: 91-95.
46. Mahalingam A, Simmons AP, Ugaonkar SR, Watson KM, Dezzutti CS, Rohan LC, Buckheit RW, Kiser PF,. 2011. Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with dual mechanism of action against HIV-1. Antimicrob Agents Chemother 55: 1650-1660.
47. Haaland RE, Evans-Strickfaden T, Holder A, Pau CP, McNicholl JM, Chaikummao S, Chonwattana W, Hart CE,. 2012. UC781 microbicide gels retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application. Antimicrob Agents Chemother 56: 3592-3596.
48. Kiser PF, Mahalingam A, Fabian J, Smith E, Damian FR, Peters JJ, Katz DF, Elgendy H, Clark MR, Friend DR,. 2012. Design of tenofovir-UC781 combination microbicide vaginal gels. J Pharm Sci 101: 1852-1864.
49. Tien D, Schnaare RL, Kang F, Cohl G, McCormick TJ, Moench TR, Doncel G, Watson K, Buckheit RW, Lewis MG, Schwartz J, Douville K, Romano JW,. 2005. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses 21: 845-853.
50. Hardy E, Jiménez AL, de Padua KS, Zaneveld LJD,. 1998. Women's preferences for vaginal antimicrobial contraceptives III: Choice of a formulation, applicator, and packaging. Contraception 58: 245-249.
51. Coggins C, Elias CJ, Atisook R, Bassett MT, Ettiègne-Traoré V, Ghys PD, Jenkins-Woelk L, Thongkrajai E, VanDevanter NL,. 1998. Women's preferences regarding the formulation of over-the-counter vaginal spermicides, AIDS 12: 1389-1391.
52. Rosen RK, Morrow KM, Carballo-Diéguez A, Mantell JE, Hoffman S, Gai F, Maslankowski L, El-Sadr WM, Mayer KH,. 2008. Acceptability of tenofovir gel as a vaginal microbicide among women in a phase I trial: A mixed-methods study. J Womens Health 17: 383-392.
53. Owen DH, Peters JJ, Lavine ML, Katz DF,. 2003. Effect of temperature and pH on contraceptive gel viscosity. Contraception 67: 57-64.
54. Katz DF, Henderson MH, Owen DH, Plenys AM, Walmer DK,. 1998. What is needed to advance vaginal formulation technology? In Vaginal microbicide formulations workshop;, Rencher WF, Ed. Philadelphia, Pennsylvania: Lippincott-Raven Publishers, pp 90-96.
55. Owen DH, Peters JJ, Katz D,. 2000. Rheological properties of contraceptive gels. Contraception 62: 321-326.
56. das Neves J, da Silva MV, Gonçalves MP, Amaral MH, Bahia MH,. 2009. Rheological properties of vaginal hydrophilic polymer gels. Curr Drug Deliv 6: 83-92.
57. Yu T, Malcolm K, Woolfson D, Jones DS, Andrews GP,. 2011. Vaginal gel drug delivery systems: Understanding rheological characteristics and performance. Expert Opin Drug Deliv 8: 1309-1322.
58. Morrow KM, Ruiz MS,. 2008. Assessing microbicide acceptability: A comprehensive and integrated approach. AIDS Behav 12: 272-283.
59. Baloglu E, Sengyigit ZA, Karavana SY, Bernkop-Schürch A,. 2009. Strategies to prolong the intravaginal residence time of drug delivery systems. J Pharm Pharm Sci 12: 312-336.
60. Di Fabio S, Van Roey J, Giannini G, van den Mooter G, Spada M, Binelli A, Pirillo MF, Germinario E, Belardelli F, de Bethune MP, Vella S,. 2003. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS 17: 1597-604.
61. Higuchi T,. 1963. Mechanisms of sustained action medication: Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 52: 1145-1149.
62. Siepmann J, Peppas NA,. 2011. Higuchi equation: Derivation, applications, use and misuse. Int J Pharm 418: 6-12.
63. Malcolm RK, Veazey RS, Greer L, Lowry D, Fetherston SM, Murphy DJ, Boyd P, Major I, Shattock RJ, Klasse PJ, Doyle LA, Rasmussen LL, Goldman L, Ketas TJ, Moore JP,. 2012. Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother 56: 2251-2258.
64. Lai BE, Xie YQ, Lavine ML, Szeri AJ, Owen DH, Katz DF,. 2008. Dilution of microbicide gels with vaginal fluid and semen simulants: Effect on rheological properties and coating flow. J Pharm Sci 97: 1030-1038.